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Abstract
Background: Loss of phosphatase and tensin homologue (PTEN) function evaluated by loss of PTEN protein
expression on immunohistochemistry (IHC) has been reported as both prognostic in metastatic colorectal cancer
and predictive of response to anti-EGFR monoclonal antibodies although results remain uncertain. Difficulties in the
methodological assessment of PTEN are likely to be a major contributor to recent conflicting results.
Methods: We assessed loss of PTEN function in 51 colorectal cancer specimens using Taqman® copy number
variation (CNV) and IHC. Two blinded pathologists performed independent IHC assessment on each specimen and
inter-observer variability of IHC assessment and concordance of IHC versus Taqman® CNV was assessed.
Results: Concordance between pathologists (PTEN loss vs no loss) on IHC assessment was 37/51 (73%). In specimens
with concordant IHC assessment, concordance between IHC and Taqman® copy number in PTEN loss assessment was
25/37 (68%).
Conclusion: Assessment PTEN loss in colorectal cancer is limited by the inter-observer variability of IHC, and discordance
of CNV with loss of protein expression. An understanding of the genetic mechanisms of PTEN loss and implementation
of improved and standardized methodologies of PTEN assessment are required to clarify the role of PTEN as a biomarker
in colorectal cancer.
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Background
Survival for patients with metastatic colorectal cancer
(mCRC) has improved significantly over the past 15 years,
largely due to improved systemic treatment options [1].
The availability of biological agents inhibiting angiogenesis
via vascular endothelial growth factor (VEGF) pathway
and targeting oncogenic cell signaling via epidermal
growth factor receptor (EGFR) have contributed to these
improved outcomes. With the advent of new treatment
options has come the search for predictive biomarkers to
assist selection of patients most likely to benefit from
these agents and equally to avoid toxicity and expense for
those who are unlikely to benefit. RAS gene mutation
(KRAS and NRAS) remains the only validated predictive
marker in mCRC and predicts for lack of benefit to anti-
EGFR monocloncal antibodies (MoAbs) cetuximab and
panitumumab [2-6]. In addition to RAS, mutation of
genes involved in downstream EGFR signaling pathways
Ras/Raf/MAPK and PI3K/AKT have been proposed to
confer resistance to anti-EGFR MoAbs [6-8]. Specifically,
mutations in BRAF and PIK3CA genes are likely to pre-
dict resistance to anti-EGFR MoAbs although analyses
on retrospective cohorts have been conflicting [7,9-11].
PTEN is an important negative regulator of PI3K/AKT
pathway and controls cell proliferation, survival and
angiogenesis. Loss of PTEN function leads to persistent
activation of the PI3K pathway and has been observed in
breast, prostate, glioblastoma, endometrial and colon can-
cers [12,13]. Loss of PTEN function, generally evaluated by
loss of PTEN protein expression, has been suggested as
both prognostic in mCRC [8,14,15] and a predictive bio-
marker for response to anti-EGFR MoAbs [16,17] although
results remain conflicting and difficult to interpret.
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Several crucial factors make testing and interpretation
of PTEN difficult. Loss of PTEN function results from
several genetic mechanisms including small scale PTEN
gene mutations (point mutations, insertions, small dele-
tions), allelic loss at chromosome 10 and epigenetic silen-
cing via hypermethylation of the PTEN promoter region
[18]. PTEN gene mutations are relatively uncommon, oc-
curring in 2.2-12% [6,19,20] of CRC specimens and there-
fore account for only a small proportion of loss of PTEN
expression on IHC staining (19-54%) [8,17,19,21]. This
highlights the role of alternate mechanisms such as allelic
loss and epigenetic silencing in impairing protein expres-
sion. These mechanisms are likely to coexist leading to a
“second hit” and resulting in bi-allelic inactivation [13,16].
Further complicating the situation, the frequency of loss
of PTEN expression increases from progression from
normal colonic mucosa to adenoma, primary CRC and
ultimately metastasis [21]. The resultant discordance
between primary and metastatic CRC has been consist-
ently demonstrated [16,17,22,23]. This highlights a major
limitation of cohort studies assessing the predictive value
of PTEN loss in mCRC patients that have used only pri-
mary CRC specimens for analysis [24-27].
Clearly the role of PTEN is more complex than KRAS
gene mutation where a single identifiable mechanism
(activating mutation), largely concordant between primary
and secondary tumours, confers near complete resistance
to anti-EGFR MoAbs. Understanding this complexity is
central to interpreting the current literature relating to
PTEN and its potential role as a predictive biomarker. Re-
cently reported cohorts of mCRC patients receiving anti-
EGFR MoAbs have used PTEN loss of IHC expression to
report loss of PTEN function. While this represents the
functional outcome of several genetic mechanisms of
PTEN loss, IHC relies on subjective interpretation and
has the potential for inter reporter variation. Furthermore
there is variability over the definition of ‘loss of PTEN’
based on IHC scoring. In the largest cohort of mCRC pa-
tients, PTEN loss was defined as no staining in any cells at
any intensity [8], while other groups have used various
cut-offs of reduced PTEN expression [17,28-30]. Others
groups investigating the predictive role of PTEN have
assessed PTEN allelic loss by fluorescent in situ hydridiza-
tion (FISH) [31], PTEN mutation [6,19,20], and PTEN
promoter methylation [16] but concordance with loss of
PTEN expression by IHC remains unclear. The consistent
demonstration of PTEN as a useful biomarker in mCRC
has been, and will continue to be, limited until assessment
of PTEN loss is better clarified and validated.
Our group undertook an analysis of PTEN status in
the AGITG MAX study of mCRC patients to identify
the rate of inter-observer variability in IHC assessment
and the rate of discordance between IHC and PCR
assessment of PTEN status.
Methods
Patients and study design
The MAX study design and eligibility criteria have been
reported previously [32].
The primary objective of this Phase III randomized
trial was to evaluate the effect of adding bevacizumab
to capecitabine (with or without mitomycin C) on pro-
gression free survival (PFS) among patients receiving
first line chemotherapy for mCRC. Four hundred and
seventy-one patients were enrolled between July 2005
and June 2007. We have used the TaqMan® Copy Number
Assay (Life Technologies, Carlsbad, CA) to assess for
PTEN allelic loss and have previously reported that loss of
PTEN copy number was not prognostic nor predictive of
outcome in the MAX trial cohort [33]. In this report
we randomly selected 59 tumor samples to explore the
potential inter-observer variability between pathologists
assessment of PTEN loss of expression by IHC, and
concordance of IHC PTEN loss and the Taqman® results
(see Figure 1). Ethics approval for translational studies was
obtained centrally.
Tumour collection and processing
Formalin-fixed, paraffin-embedded (FFPE) samples of
tumor tissue from archival specimens collected at the
time of diagnosis were retrieved from storage at hospital
pathology departments. For Copy Number PCR, gen-
omic DNA was extracted from FFPE tissue sections with
the use of the QIAamp DNA FFPE tissue kit (Qiagen,
Valencia, CA). Manual micro-dissection was performed
on samples with less than 80% malignant cells when vi-
sualized by microscopy. The same tissue blocks were
used to make tissue microarrays (TMAs) and were assessed
for PTEN expression by IHC. Researchers who assessed
PTEN IHC expression were blinded to the PCR results.
Immunohistochemistry
Immunohistochemical staining was carried out on TMAs
using the PTEN monoclonal antibody 6H2.1 (Dako,
Glostrup, Denmark) that has been used previously
[34-36]. Essentially, tissue sections (3 μm) as TMAs
were deparaffinised by heating the slides at 55-60°C
for 2 hours, then soaking in xylene and hydrating by
passing through a graded series of ethanol to water.
Antigen retrieval was carried out by microwaving the
slides in target retrieval solution pH 9 (DAKO). Endogen-
ous peroxidase was quenched by incubating the slides in
Peroxidazed I reagent (Biocare Medical, Concord, CA) for
5 min and background staining was blocked by incubation
in Background Sniper reagent (Biocare Medical). Slides
were stained using a 1:100 dilution of PTEN primary
antibody 6H2.1 and detected using the MACH 3™
mouse HRP polymer detection system according to the
manufacturer’s protocol (Biocare Medical). Slides were
Hocking et al. BMC Cancer 2014, 14:128 Page 2 of 7
http://www.biomedcentral.com/1471-2407/14/128
counterstained in methyl green (Sigma). The TMAs
contained 3 sections taken from the same core. Each
section was assessed by 2 blinded pathologists (JC
and AR) and a majority score was determined for
each pathologist (3 IHC readings). PTEN staining was
mostly cytoplasmic. Intensity was scored on a four-
tier system: 0, no staining; 1, weak; 2, moderate; and
3, strong. Loss of PTEN was defined as majority score
0 (Figure 2). The pathologist’s majority scores were
compared directly for an IHC concordance rate. Spe-
cimens concordant on IHC were used for IHC versus
TaqMan concordance rate.
PTEN copy number variation
The PTEN TaqMan® copy number assay (Hs03007912_cn,
Life Technologies) was performed using 10 ng DNA in
quadruplicate PCR. The primers provided in the assay
were entirely within exon 9 of PTEN, at cytoband
10q23.31a, location Chr.10:89727445 on NCBI build 37
(Life Technologies). The assay is a duplex PCR for the
PTEN gene and the reference gene, RNaseP (normaliser),
set up according to the supplier’s protocol and run on
the Rotorgene 6000 real time PCR instrument (Qiagen,
Valencia, CA). The results are calculated as a ratio rela-
tive to a 2-copy control using the 2-ΔΔCt method
(Rotorgene software), and multiplied by 2 to give the
copy number. We tested DNA from colon cancer cell
lines to determine the reproducibility of the assay and
to select cell lines to use as copy number controls. HT29
(ATCC) is known to have 3 copies of chromosome 10 as
determined by spectral karyotyping and comparative
genomic hybridization [37] and was used as the primary
control sample for 3 PTEN copies. Cell lines LIM2405,
LIM1899 (both a kind gift from The Ludwig Institute,
Melbourne) and HT29 were tested in quadruplicate and
repeated in 3 separate PCR assays. The assay was both
precise and reproducible - the means for LIM2405,
LIM1899 and HT29 were 1.08 SEM 0.04, 2.07 SEM 0.03
and 2.96 SEM 0.07 respectively, and the coefficient of vari-
ation (CV) from run to run was 2.4%, and intra-assay CV
was between 0.12% and 0.99%. These cell lines were there-
fore used as 1-, 2- and 3-copy controls respectively. Our
group has previously described quantification of PTEN
gene copy number on cell lines LIM2405 and LIM1899
[33]. For the patients’ DNA, loss of PTEN was defined
as ≤1.5 copies, no loss was >1.5 copies.
Results
Fifty-nine tumor specimens were analysed for loss of
copy number by Taqman® and for loss of protein expres-
sion by IHC. Eight samples were found to contain no
tumor tissue and were excluded from further analysis.
Immunohistochemistry
Two blinded pathologists assessed 51 specimens independ-
ently for PTEN protein expression with IHC. Pathologist
JC assessed 29/51 (57%) as having PTEN expression loss,
while pathologist AR assessed 17/51 (33%) as having loss
of PTEN expression. Concordance between pathologists
on final IHC assessment (PTEN loss/no loss) was 37/51
(73%), indicating in 14/51 (27%) of specimens there was
discordance in the final assessment of IHC PTEN loss
(Table 1).
Figure 1 CNV = copy number variation, IHC = immunohistochemistry, mCRC = metastatic colorectal cancer.
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Taqman® copy number PCR
Using a PTEN Taqman® copy number assay, 25/51
specimens (49%) had ≤1.5 copy number and were thus
classified as PTEN loss.
Concordance between IHC and Taqman®PCR
The 37 specimens with concordant IHC assessment
were included in the IHC versus Taqman® PCR con-
cordance analysis. Fifteen specimens had PTEN loss on
IHC of which 10 (67%) also had PTEN allelic loss on
Taqman® PCR. Seventeen specimens had PTEN allelic
loss on Taqman® PCR of which 10 (58%) had PTEN loss
on IHC. Fifteen specimens had preserved PTEN on
both IHC and Taqman® PCR analysis. Overall concord-
ance between IHC and Taqman® copy number in PTEN
loss assessment was 25/37 (68%) (Table 2).
Discussion
In this validation study of PTEN assessment in CRC we
evaluated inter-observer variability in PTEN assessment
with IHC and subsequently the discordance of PTEN
assessment between IHC and PCR based methodologies.
IHC assessment yielded rates of PTEN loss of 33% and
57% between two pathologists, while Taqman® PCR dem-
onstrated 49% of specimens contained PTEN allelic loss.
Our analysis provides particular insight into the relation-
ship between PTEN protein expression and allelic loss.
Specifically how is protein expression maintained in the
setting of allelic loss, and why do samples show absence
of PTEN expression despite allelic loss?
In samples with PTEN allelic loss 41% maintained pro-
tein expression. Of these specimens all had IHC staining
intensity of 1+ suggesting possibly a reduced level of
PTEN protein. The maintenance of protein expression
in these cases is likely due to the remaining functional
PTEN allele, which allows transcription of a normal
PTEN protein. In cases of PTEN haploinsufficiency
(monoallelic loss) whether protein expression is reduced
and whether such reduction confers a growth advantage
is unknown. Sood et al. also demonstrated monoallelic
PTEN dysfunction (by mutation or promoter methyla-
tion) resulted in loss of protein expression in only 38%
of samples, while biallelic inactivation resulted in loss of
PTEN expression in 80% of cases [16]. Ali et al. reported
a higher PTEN expression loss of 71% in samples with
a single PTEN gene mutation, though allelic loss and
methylation were not assessed [19].
In our cohort 25% of cases without PTEN allelic loss
demonstrated complete absence of PTEN expression on
IHC. These findings confirm alternative genetic mecha-
nisms, beyond allelic loss, are responsible for loss of
PTEN protein expression. Several authors have under-
taken more comprehensive analysis of PTEN status on
CRC specimens and provide an important insight into
Table 1 Loss of PTEN by IHC and CNV
PTEN loss PTEN copy number IHC score Pathologist
JC AR
NT 5 0
Loss ≤1.5 26 0 29 17
No loss >1.5 30 +1, +2, +3 22 39
Total 56 56 56
CNV copy number variation, IHC immunohistochemistry, NT no tumour
identified, PTEN phosphatase and tensin homologue.
Figure 2 Examples of immunohistochemical assessment of
PTEN (a) IHC negative (b) IHC positive.






PTEN loss (≤1.5) 10 7 17
No PTEN loss (>1.5) 5 15 20
Total 15 22 37
IHC Immunohistochemistry, PTEN phosphatase and tensin homologue.
Shaded squares = discordant results.
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the often coexisting genetic mechanisms of PTEN dys-
function. Goal et al. demonstrated hypermethylation of
the PTEN promoter region occurred in 10/132 (7.6%)
sporadic CRC specimens, with a higher rate (19.1%) in
microsatellite unstable CRCs. PTEN mutations coexisted
in 4/10 (40%) of hypermethylated PTEN specimens.
Eighty percent of patients with promoter hypermethyla-
tion had reduced (+1) or loss of PTEN protein expression
and in the 3 cases of complete loss of PTEN staining, pro-
moter hypermethylation coexisted with PTEN mutation
or allelic loss [13]. Nassif et al. assessed allelic loss and
PTEN mutation in 41 primary CRC specimens, finding 15
(37%) contained one or both aberrations. Nine of these
cases contained biallelic inactivation [12]. Perrone et al.
assessed both allelic loss by FISH and PTEN mutation in
32 mCRC samples. Thirteen percent had reduced PTEN
copy number, 10% contained PTEN mutations and only
one specimen (3%) had coexisting copy number loss
and PTEN mutation [38]. These results suggest a com-
prehensive analysis of all known mechanisms of PTEN
dysfunction, including determination of biallelic inactiva-
tion is likely to provide the most robust determination of
PTEN dysfunction.
Alternatively, focusing on loss of protein expression at
least represents the functional outcome of any such gen-
etic insult. We have demonstrated the current limita-
tions of IHC for this purpose. In our cohort, IHC
assessment of PTEN loss by two pathologists was 33%
and 57%, with overall concordance of 73%. As this was
designed as a validation subset we did not ask the two
pathologists to discuss the results that were not con-
cordant, nor seek a further opinion, methods commonly
described in papers reporting PTEN IHC aimed at redu-
cing the apparent discordance rate [10]. In all 14 cases
of IHC discordance one pathologist assessed the tumor
as having no PTEN staining (score 0) with the other
pathologist recording weak (score 1) staining. This high-
lights the subjective nature of IHC scoring, and the
inherent difficulty in arbitrary scoring of a continuous
(staining intensity) trait. The problematic inter-observer
variability of PTEN IHC is frequently reported in the lit-
erature [18,39] but rarely quantified. Recently Sangale
et al. evaluated PTEN IHC using 5 potential PTEN anti-
bodies on standardized cell lines. With the selected op-
timal antibody a validation study of 50 human tumor
specimens produced 100% concordance between three
independent pathologists using dichotomous reporting
of PTEN loss [30]. The significant inter-observer vari-
ability in PTEN IHC has also been demonstrated in
prostate and breast cancer also allowing for optimized
assays [40,41].
Overall the current literature highlight the difficulty in
accurately measuring PTEN function to date; measure-
ment of a single genetic insult, while minimizing inter-
observer variability, does not capture the often coexisting
mechanisms required for biallelic inactivation. The use of
IHC, while potentially a better measure of PTEN function,
is observer dependent and there remains a lack of consen-
sus on optimal methodology and scoring.
Given the limitations of PTEN assessment discussed
here, it is not surprising reports of the predictive value
of PTEN as a biomarker in CRC remain conflicting
[8,17,27,31]. In contrast, there appears more consistency
in the prognostic role of PTEN in colorectal cancer. Loss
of PTEN expression in primary CRC has been associated
with poor prognostic pathological features [19] as well
as higher rates of metachronous liver metastases [42].
Several retrospective cohort studies have demonstrated
reduced survival in patients with loss of PTEN by IHC
[8,14,15,43]. This is however, in contrast to our cohort of
patients from the MAX clinical trial where loss of PTEN
copy number by Taqman® PCR was not prognostic [33].
Conclusion
The lack of standardization in assessing loss of PTEN
function appears to have contributed significantly to the
conflicting results from retrospective cohort studies.
Further elucidation of PTEN as a potential biomarker
for colorectal cancer relies on defining PTEN loss of
function and standardizing analytical methods and scor-
ing systems. Future studies assessing PTEN function
may be better served by obtaining a more comprehensive
analysis of PTEN function by assessing PTEN mutation,
hypermethylation of PTEN promoter, PTEN allelic loss
and protein expression on each specimen. An alternative
approach may be to explore improved methods of meas-
uring reduced protein expression beyond IHC, given
reduced or absent protein expression should reflect the
functional outcome of PTEN loss irrespective of the gen-
etic mechanism. Immuno-PCR may provide an option of
combining the protein-specific capability of antibodies
with the objective quantification of real-time PCR [44].
This will be the focus of a future study.
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